Modarresi A, Chaibakhsh S, Koulaeinejad N, Koupaei SR. A systematic review and meta-analysis: Memantine augmentation in moderate to severe obsessive-compulsive disorder. Psychiatry Res. 2019 Dec;282:112602. doi: 10.1016/j.psychres.2019.112602. Epub 2019 Oct 4. PMID: 31630042.
- Objective: Evaluate the efficacy of memantine as a glutamate modulator for moderate to severe OCD.
- Methods: Systematic review of single, double-blinded, and open-label trials, using Y-BOCS scores as the primary measure.
- Results:
- 8 studies, 125 participants receiving memantine augmentation.
- Significant reduction of 11.73 points in Y-BOCS scores.
- Patients on memantine were 3.61 times more likely to respond than those on placebo.
- 20 mg/day memantine for at least 8 weeks is safe and effective.
- Conclusions: Memantine augmentation is a promising treatment option for moderate to severe OCD.
Gabriella True
